BioLife Solutions, Inc. (NASDAQ:BLFS) Holdings Raised by Isthmus Partners LLC

Isthmus Partners LLC lifted its position in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 34.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 165,247 shares of the medical equipment provider's stock after acquiring an additional 42,265 shares during the quarter. Isthmus Partners LLC owned 0.36% of BioLife Solutions worth $35,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in BLFS. Millrace Asset Group Inc. raised its stake in BioLife Solutions by 116.0% during the fourth quarter. Millrace Asset Group Inc. now owns 105,643 shares of the medical equipment provider's stock worth $1,717,000 after acquiring an additional 56,726 shares during the period. Granahan Investment Management LLC raised its position in shares of BioLife Solutions by 22.8% during the 4th quarter. Granahan Investment Management LLC now owns 1,292,675 shares of the medical equipment provider's stock worth $21,006,000 after purchasing an additional 240,001 shares during the period. Roubaix Capital LLC lifted its holdings in shares of BioLife Solutions by 90.8% in the 4th quarter. Roubaix Capital LLC now owns 280,337 shares of the medical equipment provider's stock worth $4,555,000 after purchasing an additional 133,439 shares during the last quarter. BNP Paribas Financial Markets boosted its position in BioLife Solutions by 249.5% during the 1st quarter. BNP Paribas Financial Markets now owns 53,515 shares of the medical equipment provider's stock valued at $993,000 after purchasing an additional 38,201 shares during the period. Finally, Sequoia Financial Advisors LLC bought a new position in BioLife Solutions during the 2nd quarter worth $466,000. Institutional investors and hedge funds own 93.24% of the company's stock.

BioLife Solutions Price Performance

Shares of BLFS stock traded down $0.94 during midday trading on Friday, reaching $23.79. 362,177 shares of the company were exchanged, compared to its average volume of 386,486. The company's 50 day moving average price is $23.34 and its two-hundred day moving average price is $20.46. The company has a market cap of $1.10 billion, a P/E ratio of -16.75 and a beta of 1.87. BioLife Solutions, Inc. has a 12 month low of $8.92 and a 12 month high of $26.73. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.81 and a current ratio of 2.86.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.08. The business had revenue of $28.33 million for the quarter, compared to analyst estimates of $23.80 million. BioLife Solutions had a negative net margin of 59.88% and a negative return on equity of 10.75%. On average, sell-side analysts expect that BioLife Solutions, Inc. will post -0.37 earnings per share for the current year.

Wall Street Analyst Weigh In

BLFS has been the topic of a number of recent research reports. TD Cowen raised their target price on BioLife Solutions from $20.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, July 17th. Northland Securities boosted their target price on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an "outperform" rating in a research note on Friday, August 9th. Craig Hallum raised their price target on shares of BioLife Solutions from $23.00 to $30.00 and gave the company a "buy" rating in a research note on Monday, August 12th. Benchmark upgraded BioLife Solutions from a "neutral" rating to a "buy" rating and set a $25.00 price objective for the company in a research report on Monday, May 13th. Finally, StockNews.com raised BioLife Solutions to a "sell" rating in a report on Friday, May 10th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Based on data from MarketBeat, BioLife Solutions has an average rating of "Moderate Buy" and an average target price of $26.20.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, CMO Todd Berard sold 10,000 shares of the company's stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $20.18, for a total value of $201,800.00. Following the completion of the sale, the chief marketing officer now directly owns 108,894 shares of the company's stock, valued at approximately $2,197,480.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Sarah Aebersold sold 3,000 shares of the business's stock in a transaction on Monday, July 1st. The stock was sold at an average price of $21.03, for a total transaction of $63,090.00. Following the sale, the insider now directly owns 61,683 shares of the company's stock, valued at $1,297,193.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Todd Berard sold 10,000 shares of the company's stock in a transaction on Friday, June 14th. The shares were sold at an average price of $20.18, for a total value of $201,800.00. Following the sale, the chief marketing officer now directly owns 108,894 shares of the company's stock, valued at $2,197,480.92. The disclosure for this sale can be found here. Company insiders own 2.20% of the company's stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.